Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Testosterone undecanoate oral - TesoRx

Next Previous
Drug Profile

Testosterone undecanoate oral - TesoRx

Alternative Names: Low-T therapy - TesoRx; Oral TRT therapy - TesoRx; Testosterone replacement therapy - TesoRx; THG 1001; TSX-011; TSX-049

Latest Information Update: 09 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TesoRx
  • Developer ASKA Pharmaceutical; TesoRx
  • Class Anabolic steroids; Androstenols; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Androgen receptor agonists; Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hypogonadism

Most Recent Events

  • 09 Jul 2025 Preclinical development is underway in Hypogonadism in USA (PO, Capsule) (TesoRx pipeline; July 2025)
  • 09 Jul 2025 TesoRx anticipates regulatory approval for TSX 049 for Hypogonadism (PO) in USA by early 2027 (TesoRx pipeline, July 2025)
  • 28 Nov 2024 No recent reports of development identified for preclinical development in Hypogonadism in USA (PO, Capsule)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top